2024-02-25 20:48:41 ET
Summary
- Exscientia's stock has been stagnant, with a 22% drop after the termination of its CEO due to inappropriate conduct.
- The company's pipeline efforts include CDK7 inhibitor GTAEXS617 and LSD1 inhibitor EXS74539, with clinical trials starting this year.
- Exscientia has entered into a collaboration with Sanofi, which could potentially bring in $45 million upfront and $300 million in milestones and royalties.
- Signals from the market, including shifts among institutional backers and a modest short interest, point to a guarded optimism, indicating potential hurdles in keeping up the momentum.
- In light of the amalgamation of breakthrough technology, solid financial health, yet mixed market sentiments, and recent executive upheaval, my recommendation shifts to "hold."
The Exscientia Experiment: When AI Meets Pharma Realities
Exscientia's ( EXAI ) stock is off 22% since my "Buy" recommendation in August. It appears I called a top. The stock has been essentially flat in the past year. The company has garnered some interest at this time due to its utilization of artificial intelligence [AI] in drug discovery. While this is an exciting application in the biotechnology sector, we also need to see progress and results in clinical trials....
Read the full article on Seeking Alpha
For further details see:
Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)